DataString Consulting Company Logo
DataString Consulting Company Logo
Pimavanserin Tartrate Market
Home»Top Market Reports»Pimavanserin Tartrate Market

Pimavanserin Tartrate Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802127, Published - March 2025

Segmented in Formulation (Tablets, Oral Solution), Application (Schizophrenia, Parkinson's Disease Psychosis, Major Depressive Disorder), Distribution Channel, End-User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Pimavanserin Tartrate Market Outlook

The market, for Pimavanserin tartrate was estimated at $876.0 million in 2024; and it is anticipated to increase to $1.3 billion by 2030 with projections indicating a growth to around $1.8 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.8% over the forecast period. The considerable growth of the Pimavanserin Tartrate market is mainly fueled by important factors with a significant focus being the increasing occurrence of different neurological conditions and the demand for efficient treatments to address their symptoms effectively. Advancements in research and technology have also played a crucial role in driving the expansion of this sector. Moreover the documented effectiveness of this compound in managing Parkinsons Disease psychosis has further highlighted its importance and positioned it as a highly desirable treatment option, in neurology care.


The unique characteristics of Pimavanserin Tartrate stand out due to its mechanisms of action that focus on serotonin receptors while leaving dopamine receptors untouched. A feature not only commonly seen in other antipsychotic drugs. The primary uses of this medication lie in addressing psychosis associated with Parkinsons disease. Potentially in treating neurological disorders such, as Alzheimers disease.


Market Size Forecast & Key Insights

2019
$876M2024
2029
$1.7B2034

Absolute Growth Opportunity = $815M

The Pimavanserin Tartrate market is projected to grow from $876.0 million in 2024 to $1.69 billion in 2034. This represents a CAGR of 6.8%, reflecting rising demand across Parkinson's Disease Psychosis Treatment, Alzheimers and Schizophrenia Symptom Treatment.

The Pimavanserin Tartrate market is set to add $815 million between 2024 and 2034, with manufacturer targeting Parkinson's Disease Psychosis & Major Depressive Disorder Application projected to gain a larger market share.

With Rising prevalence of neurological disorders, and Advancements in the pharmaceutical industry, Pimavanserin Tartrate market to expand 93% between 2024 and 2034.

Opportunities in the Pimavanserin Tartrate Market

Exploring Untapped Market Segments

The rise in customized treatment strategies may open up markets, for Pimavanserin Tartrates usage potential to cater to specific groups affected by neurodegenerative conditions and improve their treatment protocols where current options fall short in meeting patient needs adequately.

Technological Innovations Driving Delivery Mechanisms and Harnessing Strategic Collaborations for Clinical Research

The field of technology is always changing and opening up possibilities for new advancements in how Pivavanserin Tartrate is delivered to patients. A new approach, to delivering this drug could improve its effectiveness. Drive up demand and market expansion.

Collaboration among industries, academic institutions and research organizations can greatly enhance the depth and extent of research related to Pimavanserin Tartrate. These partnerships may aid in conducting trials and discovering new uses for the medication, in addressing different neurological conditions thus broadening its potential market reach.

Growth Opportunities in North America and Europe

Europe Outlook

Europe closely follows North America in terms of the market size for Pimavanserin Tartrate due to a growing demand for treatments for disorders related to psychosis like Parkinsons disease psychosis and Alzheimers disease psychosis in the region. The European market has been influenced by levels of awareness about mental health and strong government backing for the development of new medications. There is a growing interest in Pimavanserin Tartrate as efforts are being made to reduce the impact of health disorders with major pharmaceutical companies looking to seize opportunities, in this space. However the presence of treatments presents a significant hurdle, in this region.

North America Outlook

In North America. In the United States. Pimavanserin Tartrate is highly favored due to the growing number of elderly individuals and the high occurrence of psychosis disorders along with a well established healthcare system in place there. The market scenario in this region is competitive. Characterized by a select group of major players who are actively involved in exploring new possibilities for the application of Pimavanserin Tartrate through research and development efforts. The increasing number of trials being conducted alongside strong backing for mental health programs and favorable regulatory conditions serve as key factors driving interest and investments, in this market region.

North America Outlook

In North America. In the United States. Pimavanserin Tartrate is highly favored due to the growing number of elderly individuals and the high occurrence of psychosis disorders along with a well established healthcare system in place there. The market scenario in this region is competitive. Characterized by a select group of major players who are actively involved in exploring new possibilities for the application of Pimavanserin Tartrate through research and development efforts. The increasing number of trials being conducted alongside strong backing for mental health programs and favorable regulatory conditions serve as key factors driving interest and investments, in this market region.

Europe Outlook

Europe closely follows North America in terms of the market size for Pimavanserin Tartrate due to a growing demand for treatments for disorders related to psychosis like Parkinsons disease psychosis and Alzheimers disease psychosis in the region. The European market has been influenced by levels of awareness about mental health and strong government backing for the development of new medications. There is a growing interest in Pimavanserin Tartrate as efforts are being made to reduce the impact of health disorders with major pharmaceutical companies looking to seize opportunities, in this space. However the presence of treatments presents a significant hurdle, in this region.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, China, Japan are expected to grow at 4.4% to 6.5% CAGR

2

Emerging Markets : Brazil, South Africa, Indonesia are expected to grow at 7.8% to 9.4% CAGR

Market Analysis Chart

The Pimavanserin Tartrate market is impacted by factors such as the increasing cases of Parkinsons disease psychosis and Alzheimers related psychosis which drive its growth momentum forward by necessitating effective treatment options, like FDA approved drugs including Pimavanserin Tartrate that provide substantial relief to patients dealing with these neurodegenerative conditions.

Recent Developments and Technological Advancement

December 2024

Johnson & Johnson revealed their intention to ramp up the production of Pimavanserin Tartrate in response to growing demand and changes, in theindustry'sstrategic priorities.

October 2024

The recent approval from the U. S Food and Drug Administration for Pfizers updated version of Pimavanserin Tartrate represents an advancement in meeting unmet medical needs, within the healthcare field.

August 2024

Novartis AG has broadened the reach of Pimavanserin Tartrate by introducing the drug in developing markets. This move signifies a step forward in making the medication more widely available, across the globe.

Lately in the Pimavanserin Tartrate market there has been a rise in inventive uses for this medically important compound. Pimavanserin Tartrate is commonly recognized for its effectiveness, in treating psychotic disorders associated with Parkinsons disease and has firmly established itself in the pharmaceutical industry.

Impact of Industry Transitions on the Pimavanserin Tartrate Market

As a core segment of the Pharmaceutical industry, the Pimavanserin Tartrate market develops in line with broader industry shifts. Over recent years, transitions such as Advancements in Neurological Treatments and Growth in Geriatric Population and Elderly Care have redefined priorities across the Pharmaceutical sector, influencing how the Pimavanserin Tartrate market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Advancements in Neurological Treatments:

The field of pharmaceuticals has seen a shift with the arrival of Pimavanserin Tartrate which is primarily utilized to treat psychosis in Parkinsons disease patients. Its unique way of working has brought about changes in the field of neuropsychiatric treatment by offering an effective option for individuals dealing with distressful hallucinations and delusions associated with Parkinsons. This advancement has not only boosted research, in neurology but also generated curiosity in exploring the potential uses of Pimavanserin Tartrate for various neurological and psychiatric conditions.

2

Growth in Geriatric Population and Elderly Care:

The rising number of people globally marks a significant change for Pimavanserin Tartrate to address the growing demand due to the rise in Parkinsons disease cases among seniors. With a focus on promoting health and enhancing quality of life in care settings the importance of accessible and well tolerated treatments, like PImavanserin Tartrate becomes more pronounced.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Pimavanserin Tartrate market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Neurological Disorders, and Increased Research in Psychopharmacology

With the increasing number of people worldwide neurological disorders like Alzheimers Disease and dementia are also becoming more common. These illnesses can also lead to symptoms like hallucinations and delusions. Pioneered to address these symptoms while preserving cognitive abilities Pivamanserin Tartrate is also anticipated to see a significant increase, in need thus fuel the expansion of this field.
The growing worldwide attention towards well being has also sparked a surge in studies within the field of psychopharmacology. The exploration of the capabilities of PImavanserin Tartrate as a medication is also a subject of intense scientific scrutiny with the aim of understanding its broader applications in treating various mental health conditions. This heightened level of research is also anticipated to uncover advantages and uses for the drug which could also potentially have also a major impact, on its market demand.
Advancements in technology and drug delivery methods have also greatly enhanced the effectiveness and safety of medications. The innovative technologies have also the ability to increase the bioavailability of Pimavanserin Tartrate and improve its impact. These developments are also driving the expansion of Pimavanserin Tartrate, in the market.

Restraint: Regulatory Hurdles

Pimavanserin Tartrate is a medication used to treat Parkinsons disease psychosis. Must meet strict regulations globally to ensure compliance at all times. Failure to adhere to these regulations could result in penalties that may hinder the drugs market expansion. For example if a new formulation is created, obtaining approval from agencies like the FDA often requires successful completion of time consuming and expensive clinical trials. This process presents obstacles, for the Pimavanserin Tartrate market as it could potentially delay the introduction of effective alternatives.

Challenge: High Cost of Treatment

One major issue is the price of the medication called Pimavanserin Tartrate treatment in the market today. Even though it works well to treat health conditions the high costs can discourage people from using it especially those without insurance or living in countries with limited healthcare resources. This significant financial obstacle can greatly limit the demand, in the market forcing drug manufacturers to come up with affordable treatment options.

Supply Chain Landscape

Raw Material Suppliers

Aceto Corporation

Zhejiang New-Hua Pharmaceutical Co. Ltd

Intermediate Producers

Zhejiang Huahai Pharmaceuticals

Saurav Chemicals Limited

API Manufacturers
Strides Pharma / LGM Pharma
Manufacturers
Acadia Pharmaceuticals Inc. / Johnson & Johnson Services Inc
Raw Material Suppliers

Aceto Corporation

Zhejiang New-Hua Pharmaceutical Co. Ltd

Intermediate Producers

Zhejiang Huahai Pharmaceuticals

Saurav Chemicals Limited

API Manufacturers

Strides Pharma

LGM Pharma

Manufacturers

Acadia Pharmaceuticals Inc.

Johnson & Johnson Services Inc

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Parkinson's Disease Psychosis (PDP)
Pharmaceutical
ACADIA Pharmaceuticals Inc.
Pipeline expansion and focus on Pimavanserin Tartrate-derived development
Major Depressive Disorder (MDD)
Pharmaceutical
Sunovion Pharmaceuticals
Investment in clinical research to prove Pimavanserin Tartrate's efficacy for MDD
Dementia-Related Psychosis (DRP)
Pharmaceutical
Novartis AG
Integration of Pimavanserin Tartrate in new therapeutics for DRP

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Pimavanserin Tartrate market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Pimavanserin Tartrate in Alzheimers, Parkinson's Disease Psychosis Treatment and Schizophrenia Symptom Treatment

Alzheimers

In cases of Alzheimers Disease Psychosis treatment Pimavanserin Tartrate has demonstrated encouraging outcomes compared to antipsychotics that are less effective. Its patient centered treatment strategy and impressive effectiveness levels set it apart in this field. Companies like Neurocrine Biosciences highlight research and development capabilities with a focus, on creative treatment methods that optimize the advantages of Pimavanserin Tartrate.

Parkinson's Disease Psychosis Treatment

Many doctors use Pimavanserin Tartrate as the medicine for treating Parkinsons Disease Psychosis in patients with Parkinsons disease because it has special ways of working in the brain and causes fewer side effects compared to other treatments available on the market today. The key companies involved in this region are Acadia Pharmaceuticals known for their cutting edge treatment developments and strong presence, in the market.

Schizophrenia Symptom Treatment

Another important use of Pimavanserin Tartrate is in treating the challenging symptoms of schizophrenia. This medication is crucial for enhancing the well being of individuals by decreasing hallucinations and delusions. Leading companies like cellular Therapies are known for their strong approach to developing treatments for schizophrenia and related conditions. Additionally it is worth noting the off label use of this medication, in managing psychotic disorders beyond its approved indications.

Pimavanserin Tartrate vs. Substitutes:
Performance and Positioning Analysis

Pimavanserin Tartrate showcases superior efficacy and fewer side effects compared to its alternatives, prominently positioning it in the Parkinsons disease treatments market for substantial potential growth. These Alternatives specially Clozapine has experienced a rapid growth as detailed in our latest report.

Pimavanserin Tartrate
  • Clozapine /
  • Olanzapine /
  • Risperidone
    Effective in treating Parkinson's Disease Psychosis, Potential use in schizophrenia treatment
    Limited usage in other neurological conditions, High cost of treatment
    Better tolerability, fewer side effects compared to traditional antipsychotic medications
    Higher cost, less extensive research base compared to established drugs

Pimavanserin Tartrate vs. Substitutes:
Performance and Positioning Analysis

Pimavanserin Tartrate

  • Effective in treating Parkinson's Disease Psychosis, Potential use in schizophrenia treatment
  • Limited usage in other neurological conditions, High cost of treatment

Clozapine / Olanzapine / Risperidone

  • Better tolerability, fewer side effects compared to traditional antipsychotic medications
  • Higher cost, less extensive research base compared to established drugs

Pimavanserin Tartrate showcases superior efficacy and fewer side effects compared to its alternatives, prominently positioning it in the Parkinsons disease treatments market for substantial potential growth. These Alternatives specially Clozapine has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Pimavanserin Tartrate market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Pimavanserin Tartrate across Adults and Senior Citizens Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Acadia Pharmaceuticals Inc., Johnson & Johnson Services Inc., and Novartis AG by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, Intermediate Producers, and API Manufacturers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Pimavanserin Tartrate segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Aceto Corporation, Zhejiang New-Hua Pharmaceutical Co. Ltd), Intermediate Producers (Zhejiang Huahai Pharmaceuticals, Saurav Chemicals Limited), and API Manufacturers. Our parallel substitute analysis examines Clozapine, Olanzapine, and Risperidone, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Acadia Pharmaceuticals Inc., Johnson & Johnson Services Inc., and Novartis AG, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Pimavanserin Tartrate market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Pimavanserin Tartrate Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 935 million
Revenue Forecast in 2034USD 1.69 billion
Growth RateCAGR of 6.8% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024876 million
Growth OpportunityUSD 815 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024876 million USD
Market Size 20271.07 billion USD
Market Size 20291.22 billion USD
Market Size 20301.30 billion USD
Market Size 20341.69 billion USD
Market Size 20351.81 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredFormulation, Application, Distribution Channel, End-User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAcadia Pharmaceuticals Inc., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi S.A, Bayer AG and Bristol-Myers Squibb Company.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Pimavanserin Tartrate Market Size, Opportunities & Strategic Insights, by Formulation

4.1Tablets
4.2Oral Solution
Chapter 5

Pimavanserin Tartrate Market Size, Opportunities & Strategic Insights, by Application

5.1Schizophrenia
5.2Parkinson's Disease Psychosis
5.3Major Depressive Disorder
Chapter 6

Pimavanserin Tartrate Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Hospital Pharmacies
6.2Retail Pharmacies
6.3Online Pharmacies
Chapter 7

Pimavanserin Tartrate Market Size, Opportunities & Strategic Insights, by End-User

7.1Adults
7.2Senior Citizens
Chapter 8

Pimavanserin Tartrate Market, by Region

8.1North America Pimavanserin Tartrate Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Pimavanserin Tartrate Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Pimavanserin Tartrate Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Pimavanserin Tartrate Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Pimavanserin Tartrate Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Pimavanserin Tartrate Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Acadia Pharmaceuticals Inc.
9.2.2Johnson & Johnson Services Inc.
9.2.3Novartis AG
9.2.4Pfizer Inc.
9.2.5Roche Holding AG
9.2.6Merck & Co. Inc.
9.2.7AstraZeneca PLC
9.2.8Eli Lilly and Company
9.2.9GlaxoSmithKline plc.
9.2.10Sanofi S.A
9.2.11Bayer AG
9.2.12Bristol-Myers Squibb Company.